ICP-248 in Combination With Azacitidine for the Treatment in Patients With Myeloid Malignancies

NCT06656494 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

266

Enrollment

INDUSTRY

Sponsor class

Conditions

Acute Myelogenous Leukemia
Myelodysplastic Syndromes (MDS)

Interventions

DRUG: ICP-248
DRUG: Azacitidine

Sponsor

Beijing InnoCare Pharma Tech Co., Ltd.